1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
PFIZER LIMITED

PFIZER LIMITED

3,610.35
INR
-79.30
(-2.15%)
160.70EPS
27.65P/E
203.30BMarket Cap
Nov 11Next Earn
PFIZER LIMITED
BSE:PFIZER
(Bombay Stock Exchange)

Recent

price

3,610.35

P/E

ratio

27.65

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
340.91
317.67
219.52
399.53
439.84
429.76
430.26
454.95
470.27
489.27
570.7
529.46
479.3
498.6
550.69
561.75
Revenue per Share
- -
56.78
168.62
48.28
15.26
66.66
73.61
78.7
93.78
111.28
108.77
133.89
136.38
120.52
167.79
157.92
160.7
Basic EPS, GAAP
- -
7.08
-5.59
28.03
20.31
65.97
66.34
50.08
20.4
66.95
89.54
142.46
63.54
52
138.06
205.99
- -
Free Cash Flow per Basic Share
- -
4.73
6.92
253.81
0.3
10.98
15
20.05
19.9
22.5
332.1
34.92
64.96
40.1
35.03
164.3
- -
Dividend per Share
389.88
437.17
567.76
220.62
420.02
472.92
528.74
586.52
658.25
742.22
523.09
626.13
701.08
785.95
921.88
918.71
- -
Book Value per Share
389.88
437.17
567.76
220.62
230.01
292.25
354.91
403.98
487.22
583.22
376.12
490.16
576.11
663.15
801.27
800.27
- -
Tangible Book Value per Share
30
30
30
46
46
46
46
46
46
46
46
46
46
46
46
46
46
Basic Weighted Avg Shares
- -
10,173
9,480
10,043
18,277
20,123
19,662
19,685
20,814
21,515
22,384
26,110
24,223
21,927
22,810
25,193
25,698
Sales/Revenue/Turnover
- -
18.55
18.92
23.39
14.24
18.87
14.67
22.21
24.01
22.67
27.17
27.6
29.26
26.32
29.87
33.62
34.4
Operating Margin (%)
- -
96
80
80
1,311
579
629
663
714
1,032
1,094
1,150
1,055
623
608
577
576
Depreciation Expense
- -
1,694
5,032
2,209
698
3,050
3,368
3,601
4,291
5,091
4,976
6,126
6,239
5,513
7,676
7,224
7,352
Net Income, GAAP
- -
33.48
27.47
34.96
57.84
35.17
34.84
34.28
34.98
20.76
25.59
20.74
24.28
26.1
24.46
25.96
25.95
Effective Tax Rate (%)
- -
16.66
53.08
21.99
3.82
15.16
17.13
18.29
20.61
23.66
22.23
23.46
25.76
25.14
33.65
28.68
28.61
Profit Margin (%)
9,833
10,798
14,535
3,826
7,110
9,741
12,716
14,623
18,237
21,749
11,341
15,436
18,677
22,230
29,433
31,757
- -
Working Capital
- -
- -
- -
- -
25
25
25
- -
- -
887
427
1,277
933
544
676
361
- -
LT Debt
11,634
13,047
16,944
6,584
19,215
21,635
24,189
26,832
30,113
33,955
23,930
28,644
32,073
35,955
42,174
42,029
- -
Total Equity
- -
10.35
29.12
13.26
5.82
12.34
11.7
11.14
11.82
12.47
15.06
20.07
17
11.79
15.44
13.15
- -
Return on Invested Capital (%)
- -
13.76
33.57
18.79
5.43
14.93
14.7
14.1
15.09
15.84
16.9
22.45
19.9
16
19.31
16.97
- -
Return on Capital (%)
- -
13.73
33.56
18.77
5.41
14.93
14.7
14.11
15.07
15.89
17.19
23.3
20.55
16.21
19.65
17.16
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
342
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
361
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
46
46
46
Market Capitalization
227,938
215,918
203,296

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
38,032
- -
Cash, Cash Equivalents & STI
- -
30,884
- -
Accounts Receivable, Net
- -
1,818
- -
Inventories
- -
4,727
- -
Total Current Liabilities
- -
6,275
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
342
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.89%
12.15%
-0.34%
Free Cash Flow
37.9%
40.05%
49.2%
Net Income, GAAP
9.96%
9.33%
-5.88%
Sales/Revenue/Turnover
2.54%
2.88%
10.45%
Total Cash Common Dividend
177.34%
62.94%
369.04%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,629
5,886
5,380
5,919
22,810
2026
6,031
6,423
6,450
6,292
25,193
2027
6,532
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
32.94
34.61
27.89
72.34
167.79
2026
41.91
41.32
31.01
43.68
157.92
2027
44.69
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
35.03
2026
- -
- -
- -
- -
164.3
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Pfizer Limited is a pharmaceutical company primarily engaged in the development, manufacturing, marketing, and distribution of a broad range of pharmaceutical products and vaccines. Its core offerings include prescription medicines across therapeutic areas such as vaccines, oncology, cardiology, endocrinology, and inflammation; consumer healthcare products; and vaccines for various infectious diseases. The company also provides active pharmaceutical ingredients and develops innovative drug delivery systems. Pfizer Limited operates primarily in India and serves both domestic and international markets. Founded in 1950, the company is headquartered in Mumbai, Maharashtra. In the last 1-2 years, Pfizer Limited has undertaken several strategic expansions, including alliances to enhance its vaccine portfolio and collaborations for the development and commercialization of new therapies. The company has launched new vaccine products targeted at emerging infectious diseases and expanded its presence in specialty therapeutic segments. Pfizer Limited also strengthened its manufacturing capabilities with recent investments in advanced production technologies. No major name changes or restructuring have been reported during this period. Pfizer Limited targets healthcare providers, hospitals, government health programs, and retail pharmacists across India and select global markets. It operates in the pharmaceutical industry with business segments spanning innovative medicines, vaccines, and consumer healthcare. The company functions as part of the global Pfizer group but operates independently in the Indian market with its own product portfolio and market strategy.